The DFA Discussion, page-56

Even more surprising is that the COAST‘ second endpoint (anatomy) was not hit either, which is very unusual. Even in the only less sucessful DME trial where OPT-302 was combined with ELYEA, the second endpoint was hit.

“Retinal thickness measured by CST on spectral domain optical coherence tomography (SD-OCT), was reduced by -52.16 µm, from 436 µm atbaseline to 384 µm at week 12 following OPT-302 combination therapy. The mean CST was reduced by -34.92 µm, from 422 µm at baseline to 389 µm at week 12 in the Eylea control group”